Trial Profile

A Phase 1 Study Evaluating the Safety and Preliminary Efficacy of ALLO-329, a Dual Anti-CD19/Anti-CD70 Allogeneic CAR T Cell Product in Autoimmune Disease.

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 04 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ALLO 329 (Primary)
Indications Lupus nephritis; Myositis; Systemic lupus erythematosus; Systemic scleroderma
Focus Adverse reactions; First in man; Proof of concept
Acronyms RESOLUTION
Sponsors Allogene Therapeutics

Most Recent Events

25 Jul 2025 Status changed from planning to recruiting.
13 May 2025 According to an Allogene Therapeutics media release, proof-of-concept data moved to 1H 2026 to enable inclusion of both biomarker and clinical data.
28 Jan 2025 According to an Allogene Therapeutics media release, trial is scheduled to begin in mid-2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com